Inovio prices $75 million public offering of common stock and pre‑funded warrants
Inovio Pharmaceuticals announced the pricing of an underwritten public offering of 58,747,235 common shares at $1.05 each and pre‑funded warrants for 12,681,337 shares at $1.049 each. The underwriters received a 30‑day option to purchase up to 10,714,285 additional shares at the offering price. The company expects gross proceeds of about $75 million and plans to close the deal on or about November 9, 2026.
Why it matters
The company expects to raise roughly $75 million of cash before expenses, which will increase its balance‑sheet resources. Analysts note that the dilution from the offering contributed to a 25% drop in INO’s share price after the announcement.
Key facts
- 1The offering comprises 58,747,235 shares of common stock priced at $1.05 per share. prnewswire.com
- 2Pre‑funded warrants to purchase 12,681,337 shares are priced at $1.049 per warrant. prnewswire.com
- 3Underwriters have a 30‑day option to buy up to 10,714,285 additional shares at the offering price. prnewswire.com
- 4Gross proceeds are expected to be approximately $75 million before underwriting discounts and expenses. prnewswire.com
- 5The offering is expected to close on or about November 9, 2026. prnewswire.com
- 6Jefferies and Piper Sandler are acting as joint book‑running managers for the offering. prnewswire.com
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.